<DOC>
	<DOC>NCT00845728</DOC>
	<brief_summary>This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks</brief_summary>
	<brief_title>Exacerbation Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male and female adults aged â‰¥40 years, who have signed an Informed Consent form prior to initiation of any studyrelated procedure Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including: 1. Smoking history of at least 10 pack years, both current and exsmokers are eligible 2. A documented history of at least 1 moderate or severe exacerbation in the previous 12 months Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the runin period Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Tiotropium</keyword>
	<keyword>COPD</keyword>
</DOC>